Dr. Luo is a co-founder of Ensem Therapeutics. His research focuses on computer-aided drug design, computational chemistry, biophysics, and chemical biology of therapeutic targets for many diseases. Harnessing highly cross-disciplinary technologies and methods, he has developed the Lead Compound Discovery Platform and discovered innovative tool compounds for hundreds of targets. His discovery research has pioneered our understanding of how post-translational modifications affect protein dynamics and function, as well as structural mechanism and functional impact of small molecules on a broad scope of disease targets. Dr. Luo is an author of over 200 peer-reviewed publications, an inventor for more than 50 patents and patent applications, and the recipient of Wuxi AppTec Life Science and Chemistry Awards. He also served on the editorial board of Scientific Reports and ACS Bio & Med Chem Au, and was the guest editor of special issue on epigenetics of Journal of Medicinal Chemistry. For the last few years, Prof. Luo’s lab has been engaged in research collaboration with AstraZeneca and other biotech.
Dr. Luo is a Professor of the Drug Discovery and Design Center, and the Chemical Biology Center of Shanghai Institute of Materia Medica at the Chinese Academy of Sciences. He earned his Ph.D. in Organic Chemistry at Shanghai Institute of Materia Medica, and completed his post-doctoral training in chemical biology with Dr. Ronen Marmorstein at the Wistar Institute and University of Pennsylvania.